VARGATEF®: extending survival, even where you may not expect it

Alt Image

VARGATEF®: extending survival, even where you may not expect it

Alt Image

Clinical library and resources

LUME-Lung 1 trial: efficacy, VARGATEF® + Docetaxel vs Placebo + Docetaxel
Watch the mechanism of action video

Receive the latest news:

Sign up to receive information from Boehringer Ingelheim, including VARGATEF® news, data and related lung cancer pipeline and product information.

Countries where VARGATEF® is approved
Alt Image
Indications & Usage

VARGATEF® is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. 1

References
  1. VARGATEF® SmPC
FooterMobile Back to Top